Navigation Links
GERO's Wearable 2.0 Platform to Improve Performance of Activity Trackers
Date:1/8/2014

Las Vegas, NV (PRWEB) January 08, 2014

GERO Corporation today announced the launch of a collaborative effort within the Human Locomotome project to gather and analyze the data of 50,000 Fitbit, Jawbone, and Nike Fuelband users to advance early detection of chronic disease. Chronic diseases are the leading source of health care spending in the United States.

"Locomotor activity, measured by wearable accelerometers, has recently emerged as the single source of an unprecedented volume of continuous high-resolution data characterizing the day-to-day, around-the-clock physiological conditions of millions of people," said Vera Kozyr, co-founder of GERO. "We launched the Human Locomotome project together with our scientists to develop technology for early stage diagnostics by analyzing movement activity. We hope to make the information stable, reliable and accessible."

GERO Lab is a proprietary "crowd-research" wearable 2.0 platform used to collect data and involve people and partners in the study. Ultimately, the GERO Lab platform could help existing activity trackers improve product compliance.

GERO Lab will be able to take advantage of the expected growth in the wearable fitness devices market, expected to reach 90 million units globally by 2017, and another 80 million health-related ones, according to leading research firm ABI (Source: February 2012).

GERO recently conducted a study with 3000 Fitbit users, which confirmed the great potential for the GERO platform. Key takeaways of this study include:
Motor activity contains signatures of particular chronic deceases (metabolic, psychiatric, psychological).
Low-resolution trackers (e.g. Fitbit, Jawbone, etc) can also be used with GERO's mathematical model with sufficient tracking time.
GERO already detects particular health conditions with accuracy.

People who want to contribute their data to the 50K research study may sign up at http://getgero.com

Some of the chronic diseases that can be detected through locomotor activity include diabetes, hypertension, Alzheimer’s and depression. The company hopes its information will make possibly earlier interventions with an eye toward prevention.

About GERO

Moscow-based GERO was founded to develop a new technology platform using mathematical models to identify potential risks for age-related diseases through analysis of everyday movement. Data is being gathered from existing motion trackers, and as the technology evolves, users will have access to its analysis of their personal data, discovering early indicators of specific metabolic, psychiatric and neurological conditions. Armed with this knowledge, people can make health and lifestyle choices to preserve quality of life.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11463292.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Vital Connect, Aventyn Launch Wearable Biosensor Platform for Mobile Patient Monitoring
2. Global Wearable Medical Technology Market 2012 - 2016 : Worldwide Industry Latest Market Share, Growth, Size,Trends , Strategy And Forecast Research Report 2016
3. Phronetic Technologies Announces First Prenatal Smart Wearable Technology; StimElation is Poised for Production
4. Wearable Electronics Market to Reach $8.36 Billion by 2018 at a CAGR of 17.7% - New Report by MarketsandMarkets
5. Wearable Electronics & Smart Textiles Technology Expert Interview - New Announcement by MarketsandMarkets
6. Wearable artificial lung to be developed at Pitt through $3.4 million grant
7. Klingg, the Wearable Magnetic Earphone Cord Holder is Released by Mokao Design
8. Wearable cameras provide new insight into lifestyle behaviors and health
9. 2014 Mint Green Bridesmaid Dresses From Good Platform iFitDress.com
10. RURO Announces a New Version of its LIMS platform Limfinity™ - Version 4.2
11. USAFact’s New RapidFACT Screening Platform Will Launch with Multiple Website Facelifts Tied to Both Old and New Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and ... Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when he ... He explains that the Bible details the current times so plainly that anyone ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... marketing services, which specializes in thought leadership , media relations, social media, ... and services that will be powered through Act-On, an intuitive marketing automation platform. ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... jointly issued a letter to withdraw previous guidance issued by the ... identity. The guidance issued in May 2016 by the Obama Administration came in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  This report ... Thousand by the following Products: Intermediates, ... in the report include Pharmaceuticals, and Agrochemicals. The report ... Japan , Europe , and ... for the period 2015 through 2022. Also, a six-year ...
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
Breaking Medicine Technology: